COMMUNIQUÉS West-GlobeNewswire

-
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
18/04/2024 -
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024
18/04/2024 -
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
18/04/2024 -
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
18/04/2024 -
Castellum, Inc. Announces New Strategic Alliance
18/04/2024 -
Aveanna Announces First Quarter 2024 Earnings Release Date and Conference Call
18/04/2024 -
Teleflex Announces First Quarter 2024 Earnings Conference Call Information
18/04/2024 -
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
18/04/2024 -
deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer
18/04/2024 -
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
18/04/2024 -
Surgery Partners, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call Details
18/04/2024 -
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
18/04/2024 -
BioSenic S.A. : Transparency notifications received from François Rieger
18/04/2024 -
BioSenic S.A. : Notifications de transparence reçues de la part de François Rieger
18/04/2024 -
BVI Launches PODEYE Hydrophobic Monofocal IOL in Japan
18/04/2024 -
Intra-Cellular Therapies Prices Public Offering of Common Stock
18/04/2024 -
Digicann Ventures Announces Agreement to Extend Maturity Date for Convertible Debentures
18/04/2024 -
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
17/04/2024 -
NANOBIOTIX publiera ses résultats financiers et opérationnels de l'exercice 2023 le 24 avril 2024
17/04/2024
Pages